Der Anaesthesist
-
Randomized Controlled Trial Clinical Trial
Clinical neuromuscular pharmacology of AH 8165 D, an azobis-arylimidazo-pyridinium-compound.
The neuromuscular blocking properties of AH 8165 D (1,1'azobis-(3-methyl-2-phenyl-1H-imidazo-1,2a-pyridinium)dibromide) were quantitatively studied in 50 patients, undergoing extra-abdominal surgery and anaesthetized with barbiturates, nitrous oxide, fentanyl and droperidol, by means of mechanograms of the hand muscles obtained by ulnar nerve stimulation. AH 8165 D is a rapid-acting nondepolarizing agent (full effect within 1--2 min) providing good intubation conditions similar to those obtained with suxamethonium. AH 8165 D may be considered to be indicated for emergency intubation in patients with full stomach when the risk of regurgitation is high. ⋯ Repeated doses show a cumulative effect. The neuromuscular blockade can easily be reversed by an anticholinesterase drug. AH 8165 D-induced muscle relaxation is always accompanied by a dose-dependent tachycardia limiting the clinical usefulness of this new drug.
-
We have studied the high nursing requirements of an intensive-care unit. We report concerning the size of the staff required and the consequences for the hospital.